Aprogen Medicines Balance Sheet Health
Financial Health criteria checks 4/6
Aprogen Medicines has a total shareholder equity of ₩417.7B and total debt of ₩123.6B, which brings its debt-to-equity ratio to 29.6%. Its total assets and total liabilities are ₩594.4B and ₩176.7B respectively.
Key information
29.6%
Debt to equity ratio
₩123.57b
Debt
Interest coverage ratio | n/a |
Cash | ₩40.68b |
Equity | ₩417.69b |
Total liabilities | ₩176.74b |
Total assets | ₩594.43b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: A007460's short term assets (₩144.2B) exceed its short term liabilities (₩125.6B).
Long Term Liabilities: A007460's short term assets (₩144.2B) exceed its long term liabilities (₩51.1B).
Debt to Equity History and Analysis
Debt Level: A007460's net debt to equity ratio (19.8%) is considered satisfactory.
Reducing Debt: A007460's debt to equity ratio has reduced from 86.7% to 29.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A007460 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A007460 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 54% each year